Our Portfolio
We work on the best targets for patients
We have an exciting pipeline of novel, differentiated small molecules against membrane proteins and intracellular complexes – Solute Carriers, GPCRs, Inflammasome – with a focus on immunological and orphan diseases. We select targets with low translation risk through genetic association, pathway linked patient selection or immune signature stratification.

Click Target For More Info

Description Progress
Target Type Indication Discovery Lead ID Lead Optimisation Preclinical
MC2GPCROrphan endocrine disorders
GasderminIntracellular complexesBroad immunology
SLC15A4Solute carriersLupus and other IFN-opathies
KCC2Solute carriersEpilepsy including rare epilepsy disorders
Additional target validation
Insurmountable ACTH antagonism for a best-in-class profile in rare endocrine disorders.
First-in-class Gasdermin D inhibitors – a pipeline in a product.
First-in-class solute carrier inhibitor against a highly validated target in Lupus and other IFN-opathies
First-in-class solute carrier activator reducing seizures in epilepsy including rare epilepsies
First-in-class molecules driving novel anti-inflammatory biology in Inflammatory Bowel Disease.


Need more information about our pipeline?

Contact Us